Prediction of oral absorption of cinnarizine - A highly supersaturating poorly soluble weak base with borderline permeability

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 88, Issue 3, 2014, Pages 795-806

  Berlin, Mark ^a   Przyklenk, Karl Heinz ^b   Richtberg, Annette ^b   Baumann, Wolfgang ^b   Dressman, Jennifer B ^a  

^a GOETHE UNIVERSITY   (Germany)

^b Hennig Arzneimittel   (Germany)

Author keywords

Absorption; Cinnarizine; Dissolution; model; Permeability; Physiologically based pharmacokinetic; Precipitation; Supersaturation

Indexed keywords

CINNARIZINE; CINNARIZINE, DIMENHYDRINATE DRUG COMBINATION; DIMENHYDRINATE; DRUG COMBINATION;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; PRECIPITATION; PREDICTION; SENSITIVITY ANALYSIS; TABLET; TIME TO MAXIMUM PLASMA CONCENTRATION; BLOOD; DRUG COMBINATION; DRUG EFFECTS; FORECASTING; GASTROINTESTINAL ABSORPTION; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PERMEABILITY; PHYSIOLOGY; SOLUBILITY;

ADMINISTRATION, ORAL; CINNARIZINE; DIMENHYDRINATE; DRUG COMBINATIONS; FORECASTING; GASTROINTESTINAL ABSORPTION; HUMANS; MALE; PERMEABILITY; SOLUBILITY;

EID: 84912520944     PISSN: 09396411     EISSN: 18733441     Source Type: Journal    
DOI: 10.1016/j.ejpb.2014.08.011     Document Type: Article

References (44)

1. G.L. Amidon, H. Lennernas, V.P. Shah, and J.R. Crison A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm. Res. 12 1995 413 420
2. E. Galia, E. Nicolaides, D. Horter, R. Lobenberg, C. Reppas, and J.B. Dressman Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs Pharm. Res. 15 1998 698 705
3. M. Vertzoni, J. Dressman, J. Butler, J. Hempenstall, and C. Reppas Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds Eur. J. Pharm. Biopharm. 60 2005 413 417
4. E. Jantratid, N. Janssen, C. Reppas, and J.B. Dressman Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update Pharm. Res. 25 2008 1663 1676
5. C. Reppas, and M. Vertzoni Biorelevant in-vitro performance testing of orally administered dosage forms J. Pharm. Pharmacol. 64 2012 919 930
6. K. Kleberg, J. Jacobsen, and A. Mullertz Characterising the behaviour of poorly water soluble drugs in the intestine: application of biorelevant media for solubility, dissolution and transport studies J. Pharm. Pharmacol. 62 2010 1656 1668
7. J.B. Dressman, and C. Reppas In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs Eur. J. Pharm. Sci. 11 Suppl. 2 2000 S73 S80
8. K. Thelen, E. Jantratid, J.B. Dressman, J. Lippert, and S. Willmann Analysis of nifedipine absorption from soft gelatin capsules using PBPK modeling and biorelevant dissolution testing J. Pharm. Sci. 99 2010 2899 2904
9. Y. Shono, E. Jantratid, N. Janssen, F. Kesisoglou, Y. Mao, M. Vertzoni, C. Reppas, and J.B. Dressman Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling Eur. J. Pharm. Biopharm. 73 2009 107 114
10. Y. Shono, E. Jantratid, F. Kesisoglou, C. Reppas, and J.B. Dressman Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans Eur. J. Pharm. Biopharm. 76 2010 95 104
11. E. Nicolaides, M. Symillides, J.B. Dressman, and C. Reppas Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration Pharm. Res. 18 2001 380 388
12. D. Juenemann, E. Jantratid, C. Wagner, C. Reppas, M. Vertzoni, and J.B. Dressman Biorelevant in vitro dissolution testing of products containing micronized or nanosized fenofibrate with a view to predicting plasma profiles Eur. J. Pharm. Biopharm. 77 2011 257 264
13. R. Takano, K. Sugano, A. Higashida, Y. Hayashi, M. Machida, Y. Aso, and S. Yamashita Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test Pharm. Res. 23 2006 1144 1156
14. E.S. Kostewicz, M. Wunderlich, U. Brauns, R. Becker, T. Bock, and J.B. Dressman Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine J. Pharm. Pharmacol. 56 2004 43 51
15. Y.Y. Yeap, N.L. Trevaskis, and C.J. Porter The potential for drug supersaturation during intestinal processing of lipid-based formulations may be enhanced for basic drugs Mol. Pharm. 2013
16. Y.L. Hsieh, G.A. Ilevbare, B. Van Eerdenbrugh, K.J. Box, M.V. Sanchez-Felix, and L.S. Taylor PH-induced precipitation behavior of weakly basic compounds: determination of extent and duration of supersaturation using potentiometric titration and correlation to solid state properties Pharm. Res. 29 2012 2738 2753
17. E.S. Kostewicz, L. Aarons, M. Bergstrand, M.B. Bolger, A. Galetin, O. Hatley, M. Jamei, R. Lloyd, X. Pepin, A. Rostami-Hodjegan, E. Sjogren, C. Tannergren, D.B. Turner, C. Wagner, W. Weitschies, and J. Dressman PBPK models for the prediction of in vivo performance of oral dosage forms Eur. J. Pharm. Sci. 2013
18. Y. Shono, E. Jantratid, and J.B. Dressman Precipitation in the small intestine may play a more important role in the in vivo performance of poorly soluble weak bases in the fasted state: case example nelfinavir Eur. J. Pharm. Biopharm. 79 2011 349 356
19. C. Wagner, E. Jantratid, F. Kesisoglou, M. Vertzoni, C. Reppas, and J.B. Dressman Predicting the oral absorption of a poorly soluble, poorly permeable weak base using biorelevant dissolution and transfer model tests coupled with a physiologically based pharmacokinetic model Eur. J. Pharm. Biopharm. 82 2012 127 138
20. A. Kambayashi, and J.B. Dressman An in vitro-in silico-in vivo approach to predicting the oral pharmacokinetic profile of salts of weak acids: case example dantrolene Eur. J. Pharm. Biopharm. 84 2013 200 207
21. T. Jarvinen, K. Jarvinen, N. Schwarting, and V.J. Stella Beta-cyclodextrin derivatives, SBE4-beta-CD and HP-beta-CD, increase the oral bioavailability of cinnarizine in beagle dogs J. Pharm. Sci. 84 1995 295 299
22. K. Peeters, R. De Maesschalck, H. Bohets, K. Vanhoutte, and L. Nagels In situ dissolution testing using potentiometric sensors Eur. J. Pharm. Sci. 34 2008 243 249
23. S. Branchu, P.G. Rogueda, A.P. Plumb, and W.G. Cook A decision-support tool for the formulation of orally active, poorly soluble compounds Eur. J. Pharm. Sci. 32 2007 128 139
24. C.A. Bergstrom, C.M. Wassvik, K. Johansson, and I. Hubatsch Poorly soluble marketed drugs display solvation limited solubility J. Med. Chem. 50 2007 5858 5862
25. C.H. Gu, D. Rao, R.B. Gandhi, J. Hilden, and K. Raghavan Using a novel multicompartment dissolution system to predict the effect of gastric pH on the oral absorption of weak bases with poor intrinsic solubility J. Pharm. Sci. 94 2005 199 208
26. H. Ogata, N. Aoyagi, N. Kaniwa, A. Ejima, N. Sekine, K. Kitamura, and M. Inoue Gastric acidity dependent bioavailability of cinnarizine from two commercial capsules in healthy volunteers Int. J. Pharm. 29 1986
27. I. Yamada, T. Goda, M. Kawata, and K. Ogawa Application of gastric acidity-controlled beagle dog to bioavailability study of cinnarizine Yakugaku Zasshi 110 1990 280 285
28. A.T. Larsen, P. Akesson, A. Jureus, L. Saaby, R. Abu-Rmaileh, B. Abrahamsson, J. Ostergaard, and A. Mullertz Bioavailability of cinnarizine in dogs: effect of SNEDDS loading level and correlation with cinnarizine solubilization during in vitro lipolysis Pharm. Res. 2013
29. N. Koumandrakis, M. Vertzoni, C. Reppas, Increasing the biorelevance of simulated intestinal fluids for better predictions of drug equilibrium solubility in the fasted upper small intestine, 9th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Lisbon, Portugal, 31 March-3 April, 2014.
30. Y. Fei, E.S. Kostewicz, M.T. Sheu, and J.B. Dressman Analysis of the enhanced oral bioavailability of fenofibrate lipid formulations in fasted humans using an in vitro-in silico-in vivo approach Eur. J. Pharm. Biopharm. 2013
31. Hennig Arzneimittel - Data on file.
32. H. Nowacka-Krukowska, M. Rakowska, K. Neubart, and M. Kobylinska High-performance liquid chromatographic assay for cinnarizine in human plasma Acta Pol. Pharm. 64 2007 407 411
33. Guideline on the Investigation of Bioequivalence, European Medicines Agency, 2010.
34. K. Kiehm Development of a Novel Screening Tool for the Prediction of Oral Drug Absorption based on Surface Activity Profiling 2009 Shaker Verlag
35. A.C. Petereit, K. Swinney, J. Mensch, C. Mackie, S. Stokbroekx, M. Brewster, and J.B. Dressman Prediction of blood-brain barrier penetration of poorly soluble drug candidates using surface activity profiling Eur. J. Pharm. Biopharm. 75 2010 405 410
36. G.M. Grass Simulation models to predict oral drug absorption from in vitro data Adv. Drug Deliv. Rev. 23 1997 199 219
37. N. Fotaki, M. Symillides, and C. Reppas Canine versus in vitro data for predicting input profiles of l-sulpiride after oral administration Eur. J. Pharm. Sci. 26 2005 324 333
38. E.L. McConnell, H.M. Fadda, and A.W. Basit Gut instincts: explorations in intestinal physiology and drug delivery Int. J. Pharm. 364 2008 213 226
39. P. Costa, and J.M. Sousa Lobo Modeling and comparison of dissolution profiles Eur. J. Pharm. Sci. 13 2001 123 133
40. M. Lindenberg A Biopharmaceutics Classification Scheme for the Development of New Drugs 2008 Shaker Verlag p. 126
41. G.A. Kossena, W.N. Charman, B.J. Boyd, and C.J. Porter Influence of the intermediate digestion phases of common formulation lipids on the absorption of a poorly water-soluble drug J. Pharm. Sci. 94 2005 481 492
42. R. Angi, T. Solymosi, Z. Otvos, B. Ordasi, H. Glavinas, G. Filipcsei, G. Heltovics, and F. Darvas Novel continuous flow technology for the development of a nanostructured Aprepitant formulation with improved pharmacokinetic properties Eur. J. Pharm. Biopharm. 86 2014 361 368
43. Y. Wu, A. Loper, E. Landis, L. Hettrick, L. Novak, K. Lynn, C. Chen, K. Thompson, R. Higgins, U. Batra, S. Shelukar, G. Kwei, and D. Storey The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human Int. J. Pharm. 285 2004 135 146
44. C. Markopoulos, F. Thoenen, D. Preisig, M. Symillides, M. Vertzoni, N. Parrott, C. Reppas, and G. Imanidis Biorelevant media for transport experiments in the Caco-2 model to evaluate drug absorption in the fasted and the fed state and their usefulness Eur. J. Pharm. Biopharm. 86 2014 438 448